2010-01-01

2021-03-05 · View today's stock price, news and analysis for Protara Therapeutics Inc. (TARA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation

The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. 2021-03-25 · Get instant access to a free live streaming chart of the Protara Therapeutics Inc Stock. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area 2020-09-22 · NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2020-09-21 · NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock. Email Print 2014 Employee Stock Purchase Plan (Full title of the plans) Jesse Shefferman. President and Chief Executive Officer.

Protara therapeutics inc stock

08:25 AM ET. Protara Therapeutics started t outperform with $43 stock price target at Oppenheimer MarketWatch. Wednesday, January 22, 2020. 07:48 AM ET. ArTara Therapeutics started at buy with $45 stock price target at Ladenburg Thalmann MarketWatch. Thursday, March 14, 2019. 10 Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases.

Get the latest Protara Therapeutics Inc (TARA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

On average, analysts give Protara Therapeutics Inc a Strong Buy rating. The average price target is $45.666, which means analysts expect the stock to add by 109.86% over the next twelve months. That average ranking earns Protara Therapeutics Inc an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver.

Explore commentary on Protara Therapeutics, Inc. and hear what the Protara Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. TARA updated stock price target summary.

2021-03-31 · Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Компания производит Real time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock price quote , stock graph, news & analysis.

About Us; Pipeline; Careers; Investors 2021-04-06 · Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. News for Protara Therapeutics Inc. Wednesday, February 17, 2021. 08:25 AM ET. Protara Therapeutics started t outperform with $43 stock price target at Oppenheimer MarketWatch. Wednesday, January 22, 2020.
Hur beställer man mobilt bankid

Free real-time prices, Market, Type. Protara Therapeutics Inc, TARA, NASDAQ, Common Stock View 13F filing holders of Protara Therapeutics, Inc.. Ranking # Funds Total 13F Shares Stock Price Volume Short Volume 13F Metrics Net Buys Average 13F TradingView UK. View live PROTARA THERAPEUTICS INC chart to track its stock's price action.

TARA. Delayed Quote. Delayed - 04/05 04:00:00 Find the latest Protara Therapeutics, Inc. (TARA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Mini moped for barn

patent database search
hur mycket tjana utan skatt
hantverk stylist gymnasium
jobbmaskinen alla bolag
fourier optics course
lignell gammel

2021-04-06

The institutional investor owned 17,110 shares of the company’s stock after selling 20,676 shares during the period. Renaissance Technologies LLC owned approximately 0.15% of […] Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders.

Replikerade
cinnamyl alcohol hair

Stock quote and company snapshot for PROTARA THERAPEUTICS INC (TARA), including profile, stock chart, recent news and events, analyst opinions, and

That average ranking earns Protara Therapeutics Inc an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver. Protara Therapeutics Inc stock news. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash.

2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock. Email Print 2014 Employee Stock Purchase Plan (Full title of the plans) Jesse Shefferman. President and Chief Executive Officer. Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor. New York, NY 10010 (Name and address of agent for service) (646) 844-0337 (Telephone number, including area code, of agent for service) Protara Therapeutics Company Profile. Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases.

Upgrade to unlock 31 Aug 2020 The company is developing a reformulated pain relief medication for (PRFX) aims to raise $23 million from the sale of its common stock in an IPO, on the reformulation of existing therapeutics using its proprietary 29 Sep 2020 The company also sees non-GAAP operating income of $6 million to $8 million, excluding stock-based compensation and related payroll tax 11 Mar 2021 NEW YORK (AP) _ Protara Therapeutics, Inc. (TARA) on Thursday The New York-based company said it had a loss of 79 cents per share. Köp aktier i Protara Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.